96 Tests PN: B116659

Components:

45x Ab-conjugated beads (S5P10 - Human NGAL Ab-bead). PN: B116659A. One vial containing 100 µL of anti-Human NGAL conjugated to AimPlex Bead S5P10.

25x Biotin-detection (NGAL Biotin-dAb). PN: B116659B. One vial containing 100 µL of biotinylated anti-Human NGAL.

Lyophilized Standard Mix-Human Group 8, Panel B, 11-Plex. PN: HG82011. One vial containing lyophilized recombinant Cystatin C, FGF-1, FGF-19, Flt-3L, GDF-15, Granzyme B, NGAL, PAPP-A, SLPI, RAGE, and ST2.  Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

Application: Optimal antibody pair and antigen standard for assaying human Human Lipocalin-2/LCN2/NGAL. Can be multiplexed with other analytes in Human Group 8.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 50 pg/mL

  • Quantitation range:

  • LLOQ: < 100 pg/mL

  • ULOQ: > 50,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in Human Group 8: Negligible

  • Sample volume: 15 µL/test

Description:

Lipocalin-2 (LCN2), also known as oncogene 24p3 or neutrophil gelatinase-associated lipocalin (NGAL), is a protein that in humans that is involved in innate immunity by sequestrating iron that in turn, limits bacterial growth.  It is expressed in neutrophils and in low levels in the kidney, prostate, and epithelia of the respiratory and alimentary tracts. NGAL is used as a biomarker of kidney injury. In the case of acute kidney injury (AKI), NGAL is secreted in high levels into the blood and urine within 2 hours of injury. Because NGAL is protease resistant and small, the protein is easily excreted and detected in the urine. NGAL levels in patients with AKI have been associated with the severity of their prognosis and can be used as a biomarker for AKI.  NGAL can also be used as an early diagnosis for procedures such as chronic kidney disease, contrast induced nephropathy, and kidney transplant.

References:

  1. Kjeldsen L, Johnsen AH, Sengeløv H, Borregaard N (May 1993). "Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase". J. Biol. Chem. 268 (14): 10425–32. PMID 7683678.

  2. Chan P, Simon-Chazottes D, Mattei MG, Guenet JL, Salier JP (September 1994). "Comparative mapping of lipocalin genes in human and mouse: the four genes for complement C8 gamma chain, prostaglandin-D-synthase, oncogene-24p3, and progestagen-associated endometrial protein map to HSA9 and MMU2". Genomics 23 (1): 145–50. doi:10.1006/geno.1994.1470. PMID 7829063.

  3. Cowland JB, Borregaard N (October 1997). "Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans". Genomics 45 (1): 17–23. doi:10.1006/geno.1997.4896. PMID 9339356.

  4. Uttenthal LO (April 2007). "NGAL: How Useful Is the New Marker of Kidney Damage?" (PDF). CLI.